Detection and Analysis of MBC With Heterogeneous ER Expression
NCT05392985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51
Last updated 2024-02-26
Summary
To investigate the treatment pattern and efficacy of MBC patients with ER heterogeneity using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang · Fudan University
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-15
- Primary Completion
- 2022-12-15
- Completion
- 2022-12-15
Countries
- China
Study Locations
More Related Trials
-
Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients
NCT05901025 ·Status: NOT_YET_RECRUITING
-
A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China
NCT02493569 ·Status: UNKNOWN
-
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
NCT05550090 ·Status: RECRUITING
-
Target-specific immunoPET Imaging of Breast Cancer
NCT06715826 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments
NCT04212702 ·Status: UNKNOWN
-
Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer
NCT03786575 ·Status: UNKNOWN ·Phase: NA
-
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
NCT04756921 ·Status: COMPLETED
-
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
NCT01928186 ·Status: COMPLETED ·Phase: NA
-
Breast Cancer Molecular Analysis Protocol
NCT01855503 ·Status: COMPLETED
-
99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients
NCT02742168 ·Status: COMPLETED ·Phase: NA
-
Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer
NCT03592004 ·Status: UNKNOWN
-
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
NCT03947736 ·Status: UNKNOWN
-
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.
NCT05203497 ·Status: COMPLETED ·Phase: PHASE1
-
99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization
NCT03546478 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
NCT03703492 ·Status: COMPLETED ·Phase: PHASE2
-
99mTc-ABH2 SPECT/CT in Breast Cancer
NCT06194565 ·Status: RECRUITING ·Phase: NA
-
Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
NCT07252986 ·Status: RECRUITING
-
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
NCT06479460 ·Status: RECRUITING
-
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
NCT06873997 ·Status: COMPLETED
-
Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer
NCT02670668 ·Status: UNKNOWN ·Phase: NA
-
The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer
NCT01023802 ·Status: COMPLETED
-
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
NCT05510037 ·Status: COMPLETED
-
Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer
NCT05373628 ·Status: UNKNOWN ·Phase: NA
-
Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer
NCT03580837 ·Status: UNKNOWN
-
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT04332588 ·Status: RECRUITING ·Phase: PHASE1